

**EISAI RECEIVES POSITIVE OPINION FROM EMA' S CHMP ON  
ANTICANCER AGENT LENVIMA<sup>®</sup> FOR TREATMENT OF  
ADVANCED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE**  
*CHMP Opinion Based on Positive SELECT Study Data*

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its U.K. subsidiary Eisai Europe Ltd. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on anticancer agent Lenvima

Media Inquiries:  
Public Relations Department,  
Eisai Co., Ltd.  
+81-(0)3-3817-5120

**[Notes to editors]**